FDA Approves Fam-Trastuzumab Deruxtecan-nxki for Unresectable or Metastatic HR-positive, HER2-low or HER2-ultralow Breast Cancer By Ogkologos - March 6, 2025 355 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the DESTINY-Breast06 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Grants Regular Approval to Rucaparib for Metastatic Castration-Resistant Prostate Cancer FDA Approves Lisocabtagene Maraleucel for Relapsed or Refractory Marginal Zone Lymphoma Mortality Trends for Most Cancers Remain Favourable In the EU, Although the Absolute Number of Cancer Deaths Is Not Declining Due To Population Ageing MOST POPULAR Elinzanetant Leads To a Significantly Lower Frequency of Vasomotor Symptoms Associated... June 11, 2025 American Cancer Society Report Shows Economic, Racial Disparities in Cancer Outcomes December 21, 2021 ESMO Calls for Robust EU Taxation of Tobacco Products, Aiming to... September 18, 2025 Teen Quarterback Scores 8 Touchdowns A Day After His Mom Dies... November 20, 2021 Load more HOT NEWS Targeted Drug Erdafitinib Benefits Some Patients with Advanced Bladder Cancer Disease in a dish: Mini-gut organoids and the challenges of bowel... Girls Become Best Friends In Hospital, Reunite Years Later For “Survivors”... EMA Recommends Extension of Indications for Tislelizumab
